Tech Center 1600 • Art Units: 1671 1672
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18253886 | SINGLE-CHAIN ANTIBODY AGAINST FLAVIVIRUS NS1 PROTEIN | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18039818 | METHOD FOR PURIFYING VIRUS | Non-Final OA | Oxford University Innovation Limited |
| 18562053 | ANTI-NOROVIRUS ANTIBODY | Non-Final OA | Denka Company Limited |
| 18273430 | AAV PRODUCTION SYSTEMS FOR AAV VIRAL PARTICLES WITH IMPROVED INFECTIVITY | Non-Final OA | BioMarin Pharmaceutical Inc. |
| 18278876 | METHOD FOR DETECTING AND QUANTIFYING NUCLEIC ACID FROM ENVIRONMENTAL SAMPLES | Non-Final OA | Shionogi & Co., Ltd. |
| 18563019 | VACCINE FOR PREVENTION OR TREATMENT OF VIRAL INFECTION | Non-Final OA | LEMONEX INC. |
| 18251066 | Compositions and Methods for Detecting Influenza A, Influenza B, and SARS-CoV-2 | Non-Final OA | GEN-PROBE INCORPORATED |
| 18450554 | METHOD FOR INHIBITING ADVENTITIOUS VIRAL INFECTION | Non-Final OA | Allogene Therapeutics, Inc. |
| 18338054 | Multi-Epitope Vaccine Platform | Non-Final OA | Institute of Advanced Sciences |
| 18014874 | RECOMBINANT ADENOVIRUS VACCINE FOR AFRICAN SWINE FEVER AND METHOD FOR CONSTRUCTING SAME | Non-Final OA | JIAXING ANYU BIOTECHNOLOGY CO., LTD |
| 18258861 | MEANS AND METHODS OF PREVENTING, TREATING AND DETECTING INFECTIONS | Non-Final OA | LEOPOLD GMBH |
| 18258376 | USE OF A BIRNAVIRUS ALONE OR IN COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Non-Final OA | Probiogen AG |
| 18445222 | HPV Detection from urine analyte in male, non-binary and transgender patients | Non-Final OA | TELOSTRAND |
| 18039833 | METHOD FOR PRODUCING VIRUS | Non-Final OA | THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD |
| 18202836 | RSV VACCINES AND METHODS OF ADMINISTERING SAME | Non-Final OA | Meissa Vaccines, Inc. |
| 18319350 | METHODS OF PREPARING GENE THERAPIES | Non-Final OA | BridgeBio Services Inc. |
| 18030647 | METHODS FOR DETERMINING COMPLEMENT-FIXING ANTIBODIES | Non-Final OA | TAKEDA VACCINES, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy